https://pharmanovia.com/news/ https://pharmanovia.com/news/pharmanovia-announces-launch-of-korjuny-catumaxomab-in-germany-a-first-in-class-treatment-for-malignant-ascites/ 2025-12-15T12:33:36+00:00 https://pharmanovia.com/news/pharmanovia-appoints-stephan-eder-as-chief-executive-officer/ 2025-10-01T09:00:00+00:00 https://pharmanovia.com/news/pharmanovia-leadership-update/ 2025-04-10T16:05:01+00:00 https://pharmanovia.com/news/pharmanovia-acquires-exclusive-rights-to-novel-antipsychotic-treatment/ 2025-04-01T13:14:40+00:00 https://pharmanovia.com/news/pharmanovia-partners-with-echo-therapeutics-for-promotional-activities-in-australia/ 2025-03-20T11:39:26+00:00 https://pharmanovia.com/news/pharmanovia-expands-exclusive-licensing-collaboration-with-aquestive-therapeutics/ 2025-03-12T17:11:36+00:00 https://pharmanovia.com/news/pharmanovia-acquires-global-central-nervous-system-cns-portfolio-from-sanofi/ 2025-03-12T17:10:22+00:00 https://pharmanovia.com/news/pharmanovia-ceo-james-burt-appointed-chair-of-medicines-for-europes-value-adde-medicines-vam-sector-group/ 2025-03-12T17:09:44+00:00 https://pharmanovia.com/news/pharmanovia-signs-novel-biologic-in-licensing-agreement-with-lindis-biotech-to-commercialise-catumaxomab-for-treatment-of-rare-condition-malignant-ascites/ 2025-03-12T17:09:15+00:00 https://pharmanovia.com/news/pharmanovia-announces-submission-of-paediatric-investigational-plan-pip-for-elamipretide-to-the-medicines-and-healthcare-product-regulatory-agency-mhra/ 2025-03-12T17:09:05+00:00 https://pharmanovia.com/news/pharmanovia-signs-in-licensing-deal-for-novel-osteoporosis-treatment-with-radius-health/ 2025-03-12T17:08:52+00:00 https://pharmanovia.com/news/pharmanovia-announces-exclusive-distribution-agreement-with-er-kim-for-sunosi-in-eastern-europe/ 2025-03-12T17:08:38+00:00 https://pharmanovia.com/news/global-pharmaceutical-leader-sets-sight-on-sustainable-future-for-the-sector-by-setting-challenging-sbti-net-zero-target/ 2025-03-12T17:07:44+00:00 https://pharmanovia.com/news/pharmanovia-announces-new-chief-financial-officer-cfo/ 2025-03-12T17:07:09+00:00 https://pharmanovia.com/news/pharmanovia-enters-new-chemical-entity-licensing-agreement-with-stealth-biotherapeutics-to-market-and-further-develop-a-potential-novel-treatment-for-barth-syndrome/ 2025-03-12T17:05:01+00:00 https://pharmanovia.com/news/closed-loop-medicine-and-pharmanovia-enter-a-global-co-development-partnership-for-precision-medicine-combination-therapeutics/ 2025-03-12T17:04:36+00:00 https://pharmanovia.com/news/pharmanovia-received-sbti-approval-for-net-zero-emissions-targets/ 2025-03-12T17:04:13+00:00 https://pharmanovia.com/news/pharmanovia-enters-into-an-exclusive-licensing-agreement-with-aeterna-zentaris-for-the-first-and-only-orally-administered-approved-medicine-for-the-diagnosis-of-growth-hormone-deficiency-in-adults/ 2025-03-12T17:00:37+00:00 https://pharmanovia.com/news/lindis-biotech-and-pharmanovia-announce-european-marketing-authorisation-approval-for-catumaxomab-a-first-in-class-treatment-for-malignant-ascites/ 2025-03-12T16:58:36+00:00 https://pharmanovia.com/news/pharmanovia-aquires-exclusive-rights-to-treatment-for-parkinsons-disease/ 2024-11-28T17:17:42+00:00 https://pharmanovia.com/news/new-pharmanovia-study-results-reveal-chloral-hydrate-noticeably-improves-severe-insomnia-within-two-weeks/ 2024-10-29T15:19:59+00:00 https://pharmanovia.com/news/pharmanovia-appoints-new-general-manager-for-the-dach-region/ 2024-08-20T15:23:40+00:00 https://pharmanovia.com/news/closed-loop-medicine-and-pharmanovia-commence-study-for-their-first-precision-medicine-combination-therapeutic/ 2024-05-16T14:20:58+00:00 https://pharmanovia.com/news/pharmanovia-joins-irdirc-task-force-to-publish-drug-repurposing-guidebook-aimed-at-improving-care-for-people-living-with-rare-disease/ 2023-11-03T10:47:29+00:00